The Open Access Series of Imaging Studies (OASIS) is a project aimed at making neuroimaging data sets of the brain freely available to the scientific community. By compiling and freely distributing neuroimaging data sets, we hope to facilitate future discoveries in basic and clinical neuroscience.
OASIS-3 and OASIS-4 are the latest releases in the Open Access Series of Imaging Studies (OASIS) that is aimed at making neuroimaging datasets freely available to the scientific community. By compiling and freely distributing this multimodal dataset generated by the Knight ADRC and its affiliated studies, we hope to facilitate future discoveries in basic and clinical neuroscience. Previously released data for OASIS-Cross-sectional (Marcus et al, 2007) and OASIS-Longitudinal (Marcus et al, 2010) have been utilized for hypothesis driven data analyses, development of neuroanatomical atlases, and development of segmentation algorithms. OASIS-3 is a longitudinal multimodal neuroimaging, clinical, cognitive, and biomarker dataset for normal aging and Alzheimer’s Disease. OASIS-4 contains MR, clinical, cognitive, and biomarker data for individuals that presented with memory complaints.
The OASIS datasets hosted by central.xnat.org provide the community with open access to a significant database of neuroimaging and processed imaging data across a broad demographic, cognitive, and genetic spectrum an easily accessible platform for use in neuroimaging, clinical, and cognitive research on normal aging and cognitive decline. All data is available via www.oasis-brains.org.
Subjects:
MR Sessions:
Summary: This set consists of a cross-sectional collection of 416 subjects aged 18 to 96. For each subject, 3 or 4 individual T1-weighted MRI scans obtained in single scan sessions are included. The subjects are all right-handed and include both men and women. 100 of the included subjects over the age of 60 have been clinically diagnosed with very mild to moderate Alzheimer’s disease (AD). Additionally, a reliability data set is included containing 20 nondemented subjects imaged on a subsequent visit within 90 days of their initial session.
Browse Data Download CSV Download Reliability Data Fact Sheet
Subjects:
MR Sessions:
PET Sessions:
CT Sessions:
Summary: OASIS-3 is a retrospective compilation of data for 1378 participants that were collected across several ongoing projects through the WUSTL Knight ADRC over the course of 30years. Participants include 755 cognitively normal adults and 622 individuals at various stages of cognitive decline ranging in age from 42-95yrs. All participants were assigned a new random identifier and all dates were removed and normalized to reflect days from entry into study. The dataset contains 2842 MR sessions which include T1w, T2w, FLAIR, ASL, SWI, time of flight, resting-state BOLD, and DTI sequences. Many of the MR sessions are accompanied by volumetric segmentation files produced through FreeSurfer processing. PET imaging from different tracers, PIB, AV45, and FDG, totaling over 2157 raw imaging scans and the accompanying post-processed files from the Pet Unified Pipeline (PUP) are also available in OASIS-3. Additionally, 451 Tau PET sessions and post-processed PUP are now available for OASIS-3 subjects in a sub-project ‘OASIS-3_AV1451’.
Subjects:
PET Sessions:
Summary: This set is a subset of OASIS-3 subjects that have also undergone TAU (AV1451) PET imaging. For access to this project send detailed research statement to oasis-brains@nrg.wustl.edu
Subjects:
MR Sessions:
Summary: This set consists of a collection of 663 subjects aged 21 to 94. This clinical cohort was evaluated for memory disorders and dementia including clinical, csf, neurospychometric, and neuroimaging assessments. This is a unique dataset and not an update to the OASIS-3 Longitudinal Multimodal Neuroimaging dataset.
Subjects:
MR Sessions:
Summary: This set consists of a longitudinal collection of 150 subjects aged 60 to 96. Each subject was scanned on two or more visits, separated by at least one year for a total of 373 imaging sessions. For each subject, 3 or 4 individual T1-weighted MRI scans obtained in single scan sessions are included. The subjects are all right-handed and include both men and women. 72 of the subjects were characterized as nondemented throughout the study. 64 of the included subjects were characterized as demented at the time of their initial visits and remained so for subsequent scans, including 51 individuals with mild to moderate Alzheimer’s disease. Another 14 subjects were characterized as nondemented at the time of their initial visit and were subsequently characterized as demented at a later visit.
All OASIS data use requires acceptance of the Data Use Agreement
Authors of publications or presentations using OASIS data should cite relevant publications describing the methods used by the OASIS to acquire and process the data. The specific publications that are appropriate to cite in any given study will depend on what OASIS data were used and for what purposes.
When publishing findings that benefit from OASIS data, please include the relevant grant numbers as described in the Data Use Agreement in your acknowledgements section and in the associated Pubmed Central submission.
The OASIS data are distributed to the greater scientific community under the following terms:
By submitting the data request I am agreeing to abide by the terms of this data use Agreement.
These resources may be valuable to researchers using this data.
Description of imaging methods and variables for OASIS-3 (Updated July 2022)
Explaining the NIH Uniform Data System (UDS) data type
Information on how to navigate, search, and download OASIS data on XNAT central
OASIS News and Updates
Information on Freesurfer Software used for OASIS-3 volumetric segmentation
Related publications for citation or research on OASIS data
Support for the acquisition of this data and for data analysis was provided by NIH grants (as described in the Data Use Terms), the Alzheimer’s Association, the James S. McDonnell Foundation, the Mental Illness and Neuroscience Discovery Institute, and the Howard Hughes Medical Institute (HHMI) at Harvard University.
